Citi analyst Neena Bitritto-Garg lowered the firm’s price target on Neurocrine to $127 from $131 and keeps a Buy rating on the shares ahead of the Q1 results. The analyst sees a potential weak Ingrezza quarter for Neurocrine as sell-side estimates "appear too high given seasonal dynamics."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
